The authorization is valid in all EU member states as well as Iceland, Liechtenstein and Norway. It is based on the pivotal Phase 3 EASE-1 trial, in which glepaglutide significantly reduced patients’ need for parenteral support compared with placebo, together with interim data from the EASE-2 and EASE-3 extension trials and the mechanistic EASE-4 trial.

Zealand is in partnership discussions on future global commercialization of the drug. In the US, the Phase 3 EASE-5 trial is under way to support registration.

“Zeydovio combines proven efficacy with simple twice-weekly dosing, and it has the potential to meaningfully ease the burden of this disease,” says Adam Steensberg, President and CEO of Zealand Pharma.